An analysis of secondary outcomes in the SONIA trial showed that adverse events with CDK4/6 inhibitors were similar ...

Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%. Elsewhere, the ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

Shares of Gilead Sciences Inc. GILD inched 0.44% higher to $91.09 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA ...

So-called low- or minimum-volatility ETFs can still be risky. Many of them own top techs stocks and have lagged behind the ...

A claim circulating online falsely asserts the existence of a groundbreaking AIDS cure costing $40,000 annually.

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a ...

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop ...

Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to ...

Discover the new planets, moons, health advances, and ancient history uncovered in 2024.

Gilead teams up with Terray for AI-powered drug discovery, leveraging Terray’s tNova platform to accelerate the development ...

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...